With regard to treatment of outpatients with COVID-19, there is currently no evidence to support the routine use of antithrombotic agents such as aspirin, factor Xa inhibitors, or low molecular weight heparin for the prevention of arterial/venous thrombosis or COVID-19 progression, and several studies were stopped early due to lower-than-expected primary event rates (126). Here, F10 is linked to COVID-19.